Copper-67 from Iotron Medical in collaboration with CIIC
Copper-67 fromIotron Medical in collaboration with CIIC

Clinical trials experience

Despite the challenges traditionally associated with copper-67 production a number of highly successful human clinical trials have been performed with antibodies linked to copper-67 payload, demonstrating high response rates, higher tumor uptake and doses, and longer residence time in tumor than alternate radioisotopes. The targeted diseases include Non-Hodgkin Lymphoma (NHL), colon and bladder cancer.

 

New clinical trials are now underway.

Click on the links below to access published articles, or contact us for further information:

Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years

Canadian Isotope Innovations, operating the most capable radioisotope electron accelerator in North America today

Contact us today!

If you have any queries or wish to contact us:

 

For partnering opportunities:
enquiries@copper67.com

 

To buy radioisotope:

sales@copper67.com

 

 

Print Print | Sitemap
© Iotron Medical Inc 2021